Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and females aged \>=18 and =\<80 years at Screening who have a diagnosis of moderate to severely active Crohn's Disease (CD), confirmed by endoscopy or radiologic evaluation, for more than 4 months with evidence of mucosal ulceration. Patients must have all of the following:
* Crohn's Disease Activity Index (CDAI) score of \>=220 and =\<450
* A diagnosis of Crohn's Disease (CD) confirmed by ileocolonoscopy during Screening
* Presence of mucosal ulcers in at least one segment of the ileum or colon and a SES-CD score ≥7 (for patients with isolated ileal disease SES-CD score ≥4), as assessed by ileocolonoscopy and confirmed by central independent reviewer(s) before randomization
Anti-tumor necrosis factor (TNF) patients or patients previously treated with infliximab who had initially responded and who meet one of the following criteria:
* Responded and developed secondary resistance due confirmed anti-infliximab anti-drug antibody formation, which caused infliximab depletion
* Responded and became intolerant
You may not be if
Patients with ulcerative colitis or indeterminate colitis
Patients with symptomatic known obstructive strictures
Surgical bowel resection performed within 6 months prior to Screening or planned resection at any time while enrolled in the trial
Patients with an ostomy or ileoanal pouch
Patients with short bowel syndrome
Patients who have previously used infliximab and have never clinically responded
Patients who have previously received treatment with adalimumab, or who have participated in an adalimumab or adalimumab biosimilar clinical trial
Clareo Health | BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
